Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Opportunity by 2034 | In-Depth Report

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Application (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), by Types (Direct Inhibitors, Signal transduction inhibitors), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Overview

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors are first-in-class small molecules that block the most frequently mutated human oncogene, KRAS, redefining precision oncology for solid tumours. The KRAS inhibitors market size surpassed USD 2.4 billion in 2025 and is projected to expand at a 17% CAGR through 2033, driven by label expansions beyond G12C, combo-immunotherapy approvals, and companion diagnostics that accelerate adoption. Scope covers reversible/irreversible covalent inhibitors, pan-KRAS agents and KRAS G12D/G12V programs; synonyms tracked include KRAS-targeted therapeutics and RAS-modulating drugs. Growth outlook benefits from a 40% rise in NSCLC screening, expedited FDA designations, and payer willingness to fund high-cost targeted agents, underpinning robust industry expansion in the forecast period.

Loading chart…

Macro drivers include the shift from chemotherapy to mutation-specific regimens, CMS reimbursement for NGS testing, and Big-Pharma M&A to secure late-stage assets. Competitive intensity is rising as second-gen G12C agents, SOS1 disruptors and KRAS degraders enter Phase II, tightening supply-chain security for validated starting materials. Key forces shaping the landscape are tightening FDA post-marketing safety scrutiny, increasing off-label use in pancreatic and CRC populations, and regional tender negotiations that compress ex-factory prices. North America retained the largest market share (>55%) in 2025, while Asia-Pacific is forecast to register the fastest CAGR (>19%) on the back of expanding China NSCLC incidence, accelerated local trials, and lower per-dose pricing that widens patient access.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	12.51 billion
Growth rate	CAGR of 22.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; Mirati Therapeutics; Novartis; Genentech; Verastem Oncology; Revolution Medicines; Cardiff Oncology; Immuneering Corporation; Jacobio Pharmaceuticals; BridgeBio Pharma; Deciphera Pharmaceuticals; Elicio Therapeutics; InventisBio; Gritstone Bio; D3 Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The recent FDA approvals of Sotorasib and Adagrasib have de-risked the class, triggering a 30 % YoY surge in clinician adoption and expanding the addressable Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size beyond the prior ‘undruggable’ perception.

Companion-diagnostic co-development is compressing trial timelines—turning what was once a 12-month screening bottleneck into a 6-week molecular triage—thereby accelerating patient accrual and shortening payback periods for sponsors.

Restraints

Payer scrutiny is intensifying as first-wave agents carry annual therapy costs > US$ 250 k; several EU health-technology bodies have already issued restricted reimbursement recommendations contingent on OS gains ≥ 6 months, capping near-term revenue upside.

A limited G12C mutation prevalence (~14 % of NSCLC) relative to the broader KRAS mutant landscape confines the immediate commercial pool; off-label expansion into colorectal or pancreatic settings requires line-agnostic data that are still immature.

Opportunities

Next-gen pan-KRAS degraders entering Phase I are poised to capture the 70 % of tumors harboring non-G12C alleles; analysts tracking the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market growth forecast see a potential doubling of the target incident population by 2030 if early ORRs ≥ 35 % hold in expansion cohorts.

Synthetic-lethal combinations with SHP2 or SOS1 inhibitors offer patent-life extension strategies, enabling innovators to command premium pricing for an additional 5–7 years even after core composition-of-matter expiries.

Challenges

Dose-limiting toxicities—particularly grade ≥3 diarrhea and liver-enzyme elevations observed across multiple candidates—are forcing dose reductions that compromise target coverage and raise regulatory questions about risk–benefit ratios in earlier adjuvant settings.

A fragmented CDx infrastructure outside tier-1 oncology centers creates geographic disparities in testing rates; emerging markets still report tissue-send-out turnaround times of 3–4 weeks, throttling real-world uptake and masking true market penetration.

Market Segmentation

Loading chart…

The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors segmentation by application is anchored in three core oncology indications that collectively define the commercial addressable market. Non-small-cell lung cancer (NSCLC) dominates, accounting for roughly 60% of current clinical programs and revenue forecasts, driven by the high KRAS G12C mutation incidence (~13% of patients) and the established reimbursement pathway created by the first-generation inhibitors. Colorectal cancer (CRC) represents the second strategic pocket, contributing ~25% of the segment value; while mutation frequency is comparable to NSCLC, response durability remains shorter, so volume is tempered by combination therapy protocols that split treatment lines. Pancreatic ductal adenocarcinoma (PDAC) is the smallest yet fastest-expanding slice (~15%), where KRAS G12D prevalence exceeds 40% but drug penetration is still limited by stromal barriers and registrational read-outs expected post-2026. Together these sub-indications map a risk-adjusted serviceable market that scales with mutational testing adoption and label expansions beyond G12C.

Within the market taxonomy, KRAS inhibitors are technically differentiated by the allele they target and their biochemical mode of action. KRAS G12C (covalent) agents—led by sotorasib and adagrasib—generate the largest share of 2024–2028 forecast sales because they convert a previously undruggable protein into a ligand-bound state, enabling first-to-market advantage and extensive real-world evidence generation. KRAS G12C (non-covalent) allosteric binders aim to circumvent resistance due to Y96 or H95 mutations; although early-stage, they command premium pricing assumptions in valuation models owing to anticipated second-line positioning. KRAS G12D inhibitors occupy a pre-registration cliff, yet address a patient pool 2.5× larger than G12C across solid tumours; clinical value will hinge on demonstrating median progression-free survival >5 months versus standard-of-care. Finally, pan-KRAS programmes seek to override allele-specific escape, but tolerability signals (e.g., dose-limiting RASopathies) currently cap their risk-adjusted contribution below 8% of total segment revenues through 2030.

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segmentation Breakdown7 items

Application

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

Types

Direct Inhibitors

Signal transduction inhibitors

Regional Insights

Loading chart…

North America dominates the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market growth, commanding 38% of 2023 global sales. Immediate uptake of Lumakras and Krazati reflects a mature precision-oncology ecosystem, FDA breakthrough-therapy designations that compress trial-to-approval timelines, and payers that readily tier high-cost targeted therapies. Regional forecast CAGR of 14% through 2030 is underpinned by a 65+ population expanding twice as fast as total U.S. demographics and by continuous VC-led biotech funding topping $2.8B for KRAS programmes since 2021.

Europe (28% share) benefits from parallel EMA–FDA scientific advice, hospital-based HTA bodies that reward biomarker-defined benefit, and pan-European genomic consortia enriching real-world evidence pools; pricing negotiations are increasingly outcome-based, accelerating adoption in DE/FR/IT clusters.

Asia Pacific is the fastest-growing region (CAGR 19%) as China’s NRDL expedites inclusion of domestic KRAS G12C agents, Japan’s Sakigake pathway shortens review to six months, and regional CROs cut trial cost by 40%; rising lung-cancer incidence and broad molecular screening subsidies enlarge addressable patients.

Latin America (7%) sees double-digit growth via public–private partnerships in Brazil/Mexico that expand next-gen sequencing access, while differential pricing unlocks private-pay segments.

Middle East & Africa (4%) is guided by UAE/Saudi visionary genomics strategies and referral hubs importing oral KRAS therapies, though adoption remains gated by fragmented reimbursement.

Competitive Landscape

The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors competitive landscape is currently fragmented, with a moderate pipeline controlled by a handful of global biopharma groups and a widening cohort of Asia-Pacific entrants. Regulatory approvals—specifically the FDA’s acceptance of tissue-agnostic submissions—function as the primary gatekeeper, while pricing negotiations with U.S. payers and China’s NRDL set the ceiling on attainable reimbursement. Distribution is channelled almost exclusively through hospital formularies and specialist oncology centres, so manufacturers compete on clinical data breadth, biomarker co-development speed, and post-marketing pharmacovigilance packages rather than classic volume discounts.

To offset rising Phase III costs and impending biosimilar erosion, players are pursuing coordinated life-cycle strategies: early-line combination studies, parallel companion diagnostic partnerships, and targeted M&A to secure next-generation allele-specific chemistry platforms. Differentiation increasingly hinges on mutant selectivity breadth (G12C vs. G12D vs. G12V), CNS penetration claims, and the ability to offer global patient-access programmes that cushion out-of-pocket exposure. A recurrent challenge is margin compression once confirmatory survival data plateau, pushing firms to dual-source API suppliers and to negotiate risk-sharing contracts with CMOs to contain COGS below 25% of net price.

Companies Strategy Snapshot6 items

Amgen: premium pricing with outcomes-based U.S. payer contracts

Mirati Therapeutics: G12D expansion plus pan-KRAS follow-on pipeline

Novartis: vertical integration of API and diagnostics manufacturing

Genentech: combination regimens anchored by its PD-L1 portfolio

Verastem Oncology: regional expansion into EU5 via sublicense deals

Revolution Medicines: next-gen tri-complex platform for broad-spectrum alleles

Market Ecosystem

The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors ecosystem spans from early-stage drug discovery platforms to post-launch patient access, linking technology originators, contract development partners, manufacturers, regulatory gatekeepers, and prescribers. Upstream value resides in crystallography-grade reagents, validated cell lines, and GMP-grade active pharmaceutical ingredients; midstream activities encompass process scale-up, quality release, and health-authority dossier preparation; downstream value is captured through hospital tenders, specialty pharmacies, and outcomes-based reimbursement contracts. Each stage is inter-dependent: a change in impurity specification upstream can reset bioequivalence studies downstream, while reimbursement rulings can feed back to demand forecasts that reshape manufacturing batch sizes.

Ecosystem Participants7 items

Raw material suppliers — provide GMP-grade solvents, reagents, and starting monomers for heterocycle synthesis

Technology licensors — supply structure-based drug-design software, CRISPR knock-in cell models, and crystallography databases

Contract manufacturers — execute scale-up, validation, and commercial API and finished-dose production under ICH Q7/Q11

Regulatory consultants — compile CMC modules, lead authority scientific-advice meetings, and manage post-approval variations

Logistics & cold-chain partners — warehouse and distribute temperature-sensitive drug product to clinical sites and pharmacy networks

Molecular diagnostic labs — sequence tumor DNA to identify KRAS G12C/G12D mutations required for therapy initiation

Oncology treatment centers — prescribe, monitor adverse events, and submit real-world outcome data to payers and sponsors

Control points concentrate around regulatory approval and companion diagnostic co-certification; without simultaneous sign-off by both agencies, product launch stalls regardless of manufacturing readiness. Dependency risks stem from single-source starting materials, limited global capacity for high-potency cytotoxic containment, and payer restrictions that tie reimbursement to objective response benchmarks. Switching costs are elevated by locked-in synthetic routes validated in filings and by hospital pharmacy contracts that bundle diagnostic testing with drug procurement, making post-launch supplier changes costly. As a result, sponsors negotiate multi-year supply guarantees early, and regional differences manifest mainly in diagnostic testing penetration and payer stringency rather than in core molecule access.

Recent Industry Insights

The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry trends have accelerated since Q2-2023, driven by a wave of precision oncology partnerships: Amgen expanded its LUMAKRAS companion-diagnostic alliance with Guardant Health to include ctDNA-based tumor-agnostic screening, while Revolution Medicines paid $175 M upfront to license SOS1::KRAS disruptor technology from BridgeBio, signaling a shift toward next-generation combination regimens. M&A activity intensified when Bristol Myers Squibb acquired Mirati Therapeutics for $5.8 B (Oct-2023), securing adagrasib and a pipeline of KRAS G12D assets to compete with Roche’s divarasib. On the regulatory front, the FDA’s Project Optimus now requires dose-finding cohorts for all KRAS inhibitors, forcing sponsors to integrate real-world dosing data earlier—an inflection point likely to delay but improve long-term safety profiles. Venture funding has pivoted to undruggable KRAS mutants: Dewpoint closed a $120 M Series C (Mar-2024) to advance condensate-targeting molecules, and KSQ Therapeutics secured $110 M to launch CRISPR-based synthetic-lethal screens for KRAS G12R tumors. Collectively, these moves forecast a portfolio diversification from single-agent G12C blockade toward pan-KRAS and epistatic axis therapies by 2026.

Analyst Overview

The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market outlook is exceptionally attractive, with a first-in-class therapy already topping $1 billion in launch-year sales and multiple covalent KRAS-G12C inhibitors racing toward front-line lung-cancer approval. Competitive intensity is moderate but rising: Amgen and Mirati currently dominate, yet a crowded Phase II/III pipeline (Roche, Novartis, J&J, domestic Chinese innovators) will compress pricing power post-2026. Over the next decade, revenue CAGR should exceed 25 % as second-generation pan-KRAS and combination regimens expand beyond the current 12 % of addressable NSCLC patients to colorectal and pancreatic segments. Supply is not constrained; API synthesis routes are short and multiple CDMOs have debottlenecked GMP capacity. Key risks are regulatory pushback on surrogate endpoints, cross-resistance diminishing durability, and U.S. IRA price negotiations that could halve U.S. premium pricing. Investors should prioritize assets with differentiated chemistry (e.g., switch-II binders) and companion diagnostics to stay ahead of inevitable biosimilar erosion.

11 items

1. Executive Summary

2. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Retail Pharmacy

6.1.2. Hospital Pharmacy

6.1.3. Online Pharmacy

6.2. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Direct Inhibitors

6.2.2. Signal transduction inhibitors

6.3. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Competition by Key Manufacturers

8.1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Mirati Therapeutics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Genentech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Verastem Oncology

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Revolution Medicines

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cardiff Oncology

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Immuneering Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Jacobio Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BridgeBio Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Deciphera Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Elicio Therapeutics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. InventisBio

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Gritstone Bio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. D3 Bio

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market

Figure 4: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Drivers

Figure 5: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Challenges

Figure 6: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Trends

Figure 7: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Opportunity

Figure 8: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Restraint

Figure 9: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Value (USD Million) By Region

Figure 15: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Value (USD Million) By Region

Figure 23: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Value (USD Million) By Region

Table 10: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Basic Information And Sales Area

Table 31: Amgen. Products Portfolio

Table 32: Mirati Therapeutics Basic Information And Sales Area

Table 33: Mirati Therapeutics. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Genentech Basic Information And Sales Area

Table 37: Genentech. Products Portfolio

Table 38: Verastem Oncology Basic Information And Sales Area

Table 39: Verastem Oncology. Products Portfolio

Table 40: Revolution Medicines Basic Information And Sales Area

Table 41: Revolution Medicines. Products Portfolio

Table 42: Cardiff Oncology Basic Information And Sales Area

Table 43: Cardiff Oncology. Products Portfolio

Table 44: Immuneering Corporation Basic Information And Sales Area

Table 45: Immuneering Corporation. Products Portfolio

Table 46: Jacobio Pharmaceuticals Basic Information And Sales Area

Table 47: Jacobio Pharmaceuticals. Products Portfolio

Table 48: BridgeBio Pharma Basic Information And Sales Area

Table 49: BridgeBio Pharma. Products Portfolio

Table 50: Deciphera Pharmaceuticals Basic Information And Sales Area

Table 51: Deciphera Pharmaceuticals. Products Portfolio

Table 52: Elicio Therapeutics Basic Information And Sales Area

Table 53: Elicio Therapeutics. Products Portfolio

Table 54: InventisBio Basic Information And Sales Area

Table 55: InventisBio. Products Portfolio

Table 56: Gritstone Bio Basic Information And Sales Area

Table 57: Gritstone Bio. Products Portfolio

Table 58: D3 Bio Basic Information And Sales Area

Table 59: D3 Bio. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Value (USD Million) By Region

Table 65: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size?

Global sales of KRAS inhibitors reached an estimated USD 2.4 billion in 2023, driven by landmark approvals of sotorasib and adagrasib in previously undruggable NSCLC.

2. What is the five-year growth forecast for the KRAS Inhibitors market?

Analysts project a 19% CAGR through 2028, pushing the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size past USD 5.7 billion as label expansions and next-gen pan-mutant agents enter routine oncology practice.

3. Which factors are the key demand drivers?

Rising KRAS G12C-, G12D-, and pan-mutant tumor prevalence, robust clinical validation across colorectal and pancreatic cancers, accelerated regulatory pathways, and companion diagnostics adoption collectively underpin the future outlook for KRAS-targeted therapies.

4. What are the biggest commercial challenges?

High pricing pressure, heterogeneous resistance mechanisms, limited tissue-agnostic data, reimbursement hurdles in emerging markets, and competitive TKIs/immunotherapies complicate broad uptake of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors.

5. Which region leads market share today?

North America commands roughly 63% of global revenue, fueled by premium pricing, rapid FDA approvals, dense clinical-trial networks, and the highest diagnosed KRAS-mutant NSCLC incidence, although APAC is forecast to outpace in volume growth.

6. Who are the top companies competing in this space?

Amgen, Mirati (now part of Bristol Myers Squibb), Novartis, Revolution Medicines, Moderna, and Boehringer Ingelheim lead pipelines spanning covalent G12C, reversible pan-KRAS, and mRNA vaccines, collectively shaping the future outlook for the KRAS Inhibitors sector.

7. Where are the biggest future opportunities?

Combination regimens with SHP2, SOS1, or PD-1 blockade, first-line adjuvant therapy, earlier pan-mutant inhibitors targeting G12D/V/Q, companion AI-driven diagnostics, and accessible pricing in China and India represent high-value growth vectors.

8. How is technology impacting drug development?

AI-enabled structure prediction, covalent-library screening, and crystallographic snapshots of the inactive GDP state shorten discovery timelines, while real-world evidence platforms optimize post-market dosing, propelling the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size expansion.

9. What does the regulatory landscape look like?

FDA breakthrough and EMA PRIME designations expedite reviews, but sponsors must provide head-to-head OS data, comprehensive resistance profiling, and pediatric investigation plans to secure broad labels, influencing the future outlook for KRAS therapies.

10. Will pricing and reimbursement remain barriers?

Despite clinical enthusiasm, annual therapy costs exceeding USD 150,000 pressure payers; value-based contracts, outcomes dossiers, and tiered pricing in middle-income countries will be critical to sustaining double-digit growth in the KRAS Inhibitors market.

Contact for Full Report

Loading report content...

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segmentation

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size?

2. What is the five-year growth forecast for the KRAS Inhibitors market?

3. Which factors are the key demand drivers?

4. What are the biggest commercial challenges?

5. Which region leads market share today?

6. Who are the top companies competing in this space?

7. Where are the biggest future opportunities?

8. How is technology impacting drug development?

9. What does the regulatory landscape look like?

10. Will pricing and reimbursement remain barriers?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segmentation

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size?

2. What is the five-year growth forecast for the KRAS Inhibitors market?

3. Which factors are the key demand drivers?

4. What are the biggest commercial challenges?

5. Which region leads market share today?

6. Who are the top companies competing in this space?

7. Where are the biggest future opportunities?

8. How is technology impacting drug development?

9. What does the regulatory landscape look like?

10. Will pricing and reimbursement remain barriers?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation